As of 1:30 p.m. on the 10th, HLB Group affiliates and Peptron in the biotech sector are plunging and hitting their price limit floors.

HLB Pharmaceutical recorded a lower limit at 8,570 won, down 29.98% from the previous day, and Peptron also dropped to the lower limit at 111,700 won, down 29.88%.

HLB affiliates across the board showed a sharp decline as well. HLB fell 29.88% to 36,600 won, along with △HLB Therapeutics at 1,565 won (-29.82%), △HLB Biostep at 2,060 won (-27.97%), △HLB Innovation at 8,910 won (-27.20%), △HLB Global at 1,186 won (-26.56%), △HLB Panagen at 1,105 won (-25.38%), and △HLB Genex at 1,491 won (-21.85%).

In contrast, the KOSPI and KOSDAQ indices are showing a sharp upward trend at the same time, presenting a contrasting market movement. Attention is focused on whether the breadth of the decline will expand further until the market close, and whether the new leadership trend (new high leaders) will continue.

[※ This article is for reference in investment decisions, and the final responsibility for investment lies with the investor.]